Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J SMALL

Showing results (1101-1110 of 1,203) with videos related to

Pageof 121
Sort By:
European Urology|March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective StudyManuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
Research Square|April 21, 2021
Medical Care Disruptions During the First Six-Months of the COVID19 Pandemic: The Experience of Older Breast Cancer SurvivorsA Dilawari, K E Rentscher, W Zhai, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Bladder cancer. Clinical practice guidelines in oncologyJames E Montie, Robert R Bahnson, Samuel M Cohen, et al.
The Pharmacogenomics Journal|March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)Jai N Patel, Chen Jiang, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Pageof 121

Showing results (1101-1110 of 1,203) with videos related to

Sort By:
Pageof 121
European Urology|March 15, 2024
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective StudyManuel Weber, Wolfgang P Fendler, Aravind S Ravi Kumar, et al.
Research Square|April 21, 2021
Medical Care Disruptions During the First Six-Months of the COVID19 Pandemic: The Experience of Older Breast Cancer SurvivorsA Dilawari, K E Rentscher, W Zhai, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Bladder cancer. Clinical practice guidelines in oncologyJames E Montie, Robert R Bahnson, Samuel M Cohen, et al.
The Pharmacogenomics Journal|March 4, 2024
Pharmacogenetic and clinical risk factors for bevacizumab-related gastrointestinal hemorrhage in prostate cancer patients treated on CALGB 90401 (Alliance)Jai N Patel, Chen Jiang, Kouros Owzar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 22, 2018
Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2021
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E Rosenberg, Karla A Ballman, Susan Halabi, et al.
JAMA Oncology|September 23, 2021
Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate CancerRahul Aggarwal, Nicholas R Rydzewski, Li Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate CancerSusan Halabi, Qian Yang, Akash Roy, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Pageof 121